Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alphonsus J. M. van den Eertwegh"'
Autor:
Katja K.H. Aben, Carin A. Uyl-de Groot, Joan van den Bosch, Inge M. van Oort, Saskia van der Meer, Andries M. Bergman, Jules L.L.M. Coenen, Winald R. Gerritsen, Diederik M. Somford, Hans M. Westgeest, Jules Lavalaye, Alphons C.M. van den Bergh, Mathijs P. Hendriks, Maarten J. van der Doelen, Malou C.P. Kuppen, Filiz Celik, Marco B. Polee, Alphonsus J. M. van den Eertwegh
Publikováno v:
Kuppen, M C, Westgeest, H M, van der Doelen, M J, van den Eertwegh, A J, Coenen, J L, Aben, K K, van den Bergh, A C, Bergman, A M, den Bosch, J V, Celik, F, Hendriks, M P, Lavalaye, J, der Meer, S V, Polee, M B, Somford, D M, van Oort, I M, Uyl-de Groot, C A & Gerritsen, W R 2020, ' Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer ', Future Oncology, vol. 16, no. 19, pp. 1371-1384 . https://doi.org/10.2217/fon-2020-0039
Future Oncology, 16(19), 1371-1384. Future Medicine Ltd.
Future Oncology, 16, 19, pp. 1371-1384
Future oncology, 16(19), 1371-1384. FUTURE MEDICINE LTD
Future Oncology, 16, 1371-1384
Future Oncology, 16(19), 1371-1384. Future Medicine Ltd.
Future Oncology, 16, 19, pp. 1371-1384
Future oncology, 16(19), 1371-1384. FUTURE MEDICINE LTD
Future Oncology, 16, 1371-1384
Item does not contain fulltext Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b016678894ad456a0d9a4e1e94d887b8
https://pure.eur.nl/en/publications/f28d6113-b2c9-48d2-b4bf-904818fb828d
https://pure.eur.nl/en/publications/f28d6113-b2c9-48d2-b4bf-904818fb828d
Autor:
Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink
Publikováno v:
European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV
Background: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028
Autor:
Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl
Publikováno v:
Clinical Genitourinary Cancer, 17, 5, pp. e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956
In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55db3d2d7c2abd92a4b76a9b4278c5e
https://doi.org/10.1016/j.clgc.2019.05.018
https://doi.org/10.1016/j.clgc.2019.05.018
Autor:
Igor Cordia, Joan van den Bosch, Hans M. Westgeest, Aad I. de Vos, Lidwine W. Tick, Ronald de Wit, Marco B. Polee, Maud M. Geenen, Alphonsus J. M. van den Eertwegh, Frank P. J. Peters, Mathijs P. Hendriks, Roan Spermon, Michiel O. Boerma, Carin A. Uyl-de Groot, Winald R. Gerritsen, Harrie P. Beerlage, Agnes J. van de Wouw, Alphonsus C. M. van den Bergh, Jules L.L.M. Coenen, Monique M.E.M. Bos, Reindert J.A. van Moorselaar, Pieter van den Berg, Haiko J. Bloemendal
Publikováno v:
European Urology Focus, 4(5), 694. Elsevier BV
European Urology Focus, 4, 694-701
European urology focus, 4(5), 694-701. Elsevier BV
European Urology Focus, 4(5), 694-701. Elsevier BV
European Urology, 4(5), 694-701. Elsevier
European Urology Focus, 4, 5, pp. 694-701
Westgeest, H M, Uyl-de Groot, C A, van Moorselaar, R J A, de Wit, R, van den Bergh, A C M, Coenen, J L L M, Beerlage, H P, Hendriks, M P, Bos, M M E M, van den Berg, P, van de Wouw, A J, Spermon, R, Boerma, M O, Geenen, M M, Tick, L W, Polee, M B, Bloemendal, H J, Cordia, I, Peters, F P J, de Vos, A I, van den Bosch, J, van den Eertwegh, A J M & Gerritsen, W R 2018, ' Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Focus, vol. 4, no. 5, pp. 694-701 . https://doi.org/10.1016/j.euf.2016.09.008
European Urology Focus, 4, 694-701
European urology focus, 4(5), 694-701. Elsevier BV
European Urology Focus, 4(5), 694-701. Elsevier BV
European Urology, 4(5), 694-701. Elsevier
European Urology Focus, 4, 5, pp. 694-701
Westgeest, H M, Uyl-de Groot, C A, van Moorselaar, R J A, de Wit, R, van den Bergh, A C M, Coenen, J L L M, Beerlage, H P, Hendriks, M P, Bos, M M E M, van den Berg, P, van de Wouw, A J, Spermon, R, Boerma, M O, Geenen, M M, Tick, L W, Polee, M B, Bloemendal, H J, Cordia, I, Peters, F P J, de Vos, A I, van den Bosch, J, van den Eertwegh, A J M & Gerritsen, W R 2018, ' Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Focus, vol. 4, no. 5, pp. 694-701 . https://doi.org/10.1016/j.euf.2016.09.008
Background: Trials in castration-resistant prostate cancer (CRPC) treatment have shown improved outcomes, including survival. However, as trial populations are selected, results may not be representative for the real-world population. The aim of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a75f4ab2a0be6bc966c310e3b85a39
https://doi.org/10.1016/j.euf.2016.09.008
https://doi.org/10.1016/j.euf.2016.09.008